Parkinson's Disease Biomarkers That Work

At the recent Society for Neuroscience Annual Meeting in San Diego, Charles River presented the following posters on Parkinson’s disease. The posters highlight the utility of a multi-modal approach to test established Parkinson’s disease rodent models for clinically relevant endpoints such as movement changes and cognitive decline. Additionally, some of the posters show the effects of LRRK2 inhibitors and other PD therapies on the phenotype of PD animal models.

Biomarkers of Parkinson's Disease

Learn More About our Parkinson’s Disease Discovery Capabilities